Congress orders study to weaken drug manufacturing rules—without assessing public health cost
H.R. 1405 — Enhancing Domestic Drug Manufacturing Competitiveness Act · Filed by Vern Buchanan (R-FL) · 1 cosponsor · Introduced Feb 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Government Accountability Office (GAO) to study what federal regulations are slowing down or making more expensive the construction and expansion of pharmaceutical manufacturing plants in the United States, and to compare those barriers to regulations in other countries. The GAO will interview industry stakeholders, assess the time and cost impact of environmental and other rules, and recommend ways regulators could speed up approvals and inspections to make the U.S. a more competitive location for drug manufacturing.
Why we flagged it
The bill's core function is a study, not direct deregulation. However, the framing—asking how to make U.S. rules 'less burdensome' relative to other countries and requesting 'streamlining' recommendations—signals intent to reduce regulatory friction, likely environmental and safety reviews. This is a soft-power deregulation bill disguised as fact-finding.
What the text implies
- The study's focus on comparing U.S. regulations unfavorably to other countries (which may have weaker environmental or safety standards) may be used to justify rollbacks of FDA, EPA, or OSHA rules without explicit legislative action.
- Recommendations to 'expedite reviews, inspections, and approvals' could lead to reduced scrutiny of manufacturing practices, potentially increasing risk of contamination, quality failures, or worker safety issues.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers; contract manufacturing organizations (CMOs); pharmaceutical equipment suppliers